Welcome to ARVO Insight

In this issue

ARVO responds to NIH proposed definition of clinical trials

ARVO leadership recently responded to the National Institutes of Health’s redefinition of clinical trials in a letter expressing concern regarding the potential for broad interpretation of the new definition and its resulting impacts on eye and vision scientists.

The ARVO leadership echoed “concerns expressed by others that classifying basic human research as clinical trials can confuse the public about the nature of trials and that the additional studies categorized as trials will place additional and undue burden on NIH oversight, on researchers and their institutions …” 

ARVO opposes cuts to NIH grants

ARVO joined 108 other organizations in opposing the Trump Administration’s proposal to reduce reimbursement for Facilities and Administrative (F&A) Costs in National Institutes of Health (NIH) grants. The proposed reduction in indirect cost reimbursement would account for the majority of the $7.2 billion (21%) cut proposed by the president in FY2018 funding to NIH. ARVO signed onto a letter to the Department of Health and Human Services Secretary Tom Price, MD, and Office of Management and Budget Director (OMB) Director Mick Mulvaney.

Advertisement
Harrington tower ad